研究噻托溴铵联合福多司坦治疗支气管扩张症急性加重的疗效及其对炎症因子的影响

Study the Efficacy of Tiotropium Bromide Combined with Fudosteine in the Treatment of Acute Exacerbation of Bronchiectasis and its Effect onInflammatory Factors

目的研究噻托溴铵联合福多司坦治疗支气管扩张症急性加重的疗效及其对炎症因子的影响。方法方便选择在2018年10月-2019年9月在该院呼吸与危重症医学科确诊为支气管扩张症急性加重的患者。将患者随机分配为两组,观察组40例,对照组42例,对照组实施常规治疗,观察组在常规治疗的同时加用噻托溴铵粉吸入剂+福多司坦片口服治疗。治疗后对比两组患者临床症状评分及炎症因子水平,炎症因子包括血清超敏C反应蛋白及白介素-6水平。结果观察组和对照组治疗后(2.05±1.33)分、(2.74±1.54)分对比治疗前(6.32±1.69)分、(5.89±1.75)分临床症状评分均有下降,血清超敏C反应蛋白(22.03±8.57)mg/L、(30.11±9.45)mg/L较治疗前(95.33±31.21)mg/L、(91.64±27.21)mg/L明显下降,白介素-6水平(5.03±1.08)pg/mL、(6.92±1.34)pg/mL较治疗前(35.27±8.03)pg/mL、(37.42±9.19)pg/mL明显下降;观察组经治疗后临床症状评分(2.05±1.33)分下降更优于对照组(2.74±1.54)分,差异有统计学意义(t=2.424,P<0.05),且观察组炎症因子超敏C反应蛋白(22.03±8.57)mg/L及白介素-6(5.03±1.08)pg/mL水平下降更优于对照组分别为(30.11±9.45)mg/L,(6.92±1.34)pg/mL,二者差异有统计学意义(t=18.539,P<0.01;t=7.718,P<0.05)。结论噻托溴铵联合福多司坦治疗支气管扩张症急性发作患者,改善患者症状效果更优,并能更有效降低炎症因子水平,改善预后。

Objective To study the effect of tiotropium bromide combined with fudosteine on acute exacerbation of bronchiectasis and its effect on inflammatory factors.Methods Convenient selection patients diagnosed with acute exacerbation of bronchiectasis in the Department of Respiratory and Critical Care Medicine of our hospital from October 2018 to September 2019.The patients were randomLy divided into two groups,40 cases in the observation group and 42 cases in the control group.The control group was given routine treatment.The observation group was given oral treatment with tiotropium bromide powder inhalation+fudosteine tablets in addition to conventional treatment.After treatment,the clinical symptom scores and inflammatory factor levels of the two groups of patients were compared.The inflammatory factors included serum high-sensitivity C-reactive protein and interleukin-6 levels.Results The observation group and the control group after treatment(2.05±1.33)points,(2.74±1.54)points compared with before treatment(6.32±1.69)points,(5.89±1.75)points,the clinical symptom scores decreased,and the serum high-sensitivity C-reactive protein(22.03±8.57)mg/L,(30.11±9.45)mg/Lwas significantly lower than before treatment(95.33±31.21)mg/L,(91.64±27.21)mg/L,and interleukin-6 levels(5.03±1.08)pg/mL,(6.92±1.34)pg/mL were higher than before treatment(35.27±8.03)pg/mL,(37.42±9.19)pg/mLdecreased significantly;the clinical symptom score(2.05±1.33)points of the observation group after treatment was better than the control group(2.74±1.54)points,the difference was statistically significant(t=2.424,P<0.05),and the observation group of the inflammatory factor hypersensitivity C-reactive protein(22.03±8.57)mg/L and interleukin-6(5.03±1.08)pg/mL decreased more than the control group(30.11±9.45)mg/L,(6.92±1.34)pg/mL,respectively there was a statistical difference between the two(t=18.539,P<0.01;t=7.718,P<0.05).Conclusion Tiotropium bromide combined with fudosteine is more effective in improving the symptoms of patients with bronchiectasis,and can effectively reduce the level of inflammatory factors and improve the prognosis.